Summary
Analysis of trends shaping the continuing evolution of the biotech sector and
critical success factors for company growth. Datamonitor benchmarks the growth
strategies of leading technology platform, developing and fully integrated
biotechs, and the tactics they employ to increase their market cap. Finally,
Datamonitor offers best practice recommendations to optimize biotech companies'
future growth potential and assesses their impact on pharma-biotech
relationships.
MESSAGE TO THE INDUSTRY
Biotechnology companies have traditionally been subordinate partners in
their relationships with large pharmaceutical companies. However, more recently
some biotechnology companies have been able to avoid these restrictive
agreements by offering a unique service proposition. These companies have been
able to extract a 'partnership premium' that offers greater commercial freedom
to drive their own growth.
The urge to gain commercial freedom by other companies has seen an increasing
trend for bypassing pharmaceutical partners altogether. By forming
intra-biotechnology collaborations, companies that are unable to command a
'partnership premium' can apply the capabilities of others to develop products
and retain a greater revenue share. This allows collaboration partners to speed
their transition to a fully integrated biotechnology company, commonly the
ultimate aim. These collaborations are expected to become increasingly common,
resulting in biotechnology companies that are more competitive with the
capabilities to squeeze the market share of pharmaceutical companies.
Biotechnology Company Growth Strategies - Intra-Biotech Collaborations Bring
Independence from Pharma One Step Closer provides an in-depth analysis of the
top 20 biotechnology companies by market capitalization, examining five
companies from each of the four stages of the biotechnology growth curve. Based
on analysis of their growth strategies as well as primary research, Datamonitor
Healthcare provides best practice recommendations for maximizing future
performance.
You will gain access to:
- Analysis of strategic growth priorities for biotechnology companies at
various stages of business model evolution .
- In-depth case studies of the top 20 biotechnology companies including
technology platform, codeveloping, developing and fully integrated companies
.
- Over 50 data tables showing agreement structure and format, deal size and
financial analysis for each company .
- Analysis of the drivers and resistors of current growth strategy and
forecasts for future growth strategies for each company .
- Primary research based analysis of the factors affecting the
biopharmaceutical market in the future and scenario-based forecasting
showing their future impact on company strategy .
- Predictive analysis of the impact that the evolving biopharmaceutical
sector will have on the pharmaceutical market and best practice strategic
recommendations for maximizing growth
View Cart
